abstract details

The summaries are free for public use. ARTHROS will continue to add and archive summaries of articles deemed relevant to ARTHROS by our Faculty.

Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study

Author

J Clin Med. 2020 Apr 24;9(4):E1227.doi: 10.3390/jcm9041227.

Maria Antonietta Barbieri 1, Giuseppe Cicala 1, Paola Maria Cutroneo 2, Elisabetta Gerratana 1, Caterina Palleria 3, Caterina De Sarro 3, Ada Vero 3, Luigi Iannone 3, Antonia Manti 3, Emilio Russo 3, Giovambattista De Sarro 3, Fabiola Atzeni 1, Edoardo Spina 1

Author Information

1. Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy.

2. Sicilian Regional Pharmacovigilance Centre, University Hospital of Messina, 98125 Messina, Italy.

3. Department of Health Science, School of Medicine, University of Catanzaro, Clinical Pharmacology and Pharmacovigilance Unit, Mater Domini Hospital, 88100 Catanzaro, Italy.

Abstract

Post-marketing surveillance activities are essential to detect the risk/benefit profile of biologic disease-modifying antirheumatic drugs (bDMARDs) in inflammatory arthritis. The aim of this study was to evaluate adverse events (AEs) in patients treated with bDMARDs in rheumatology during a prospective pharmacovigilance study from 2016 to 2018. Descriptive statistical analyses were performed to evaluate bDMARDs-related variables of patients without AEs/failures vs patients with AEs and failures. The risk profile among biologics was assessed by comparing patients treated with each bDMARD to patients treated with etanercept. A total of 1155 patients were enrolled, mostly affected by rheumatoid arthritis (46.0%). AEs and failures were experienced by 8.7% and 23.3%, respectively. The number of comorbidities significantly influenced the onset of AEs, while anxiety-depressive, gastrointestinal disease, and fibromyalgia influenced onset of failures. The probability of developing an AE was significantly lower in patients treated with secukinumab, while the probability of developing treatment failure was significantly lower in patients treated with golimumab, secukinumab and tocilizumab. A total of 216 AEs were reported (25.5% serious), mostly regarding infections (21.8%), musculoskeletal (17.6%) and skin (16.2%) disorders. Serious AEs included neutropenia (12.7%), lymphocytosis (9.1%) and uveitis (7.3%). The obtained results revealed known AEs but real-world data should be endorsed for undetected safety concerns.